CorEvitas Multiple Sclerosis registry for people starting MS medicine
Part of Brain & nervous system, Immune system & allergy clinical trials.
This registry collects health information from adults with multiple sclerosis (MS) when they start an MS medicine. It may help researchers better understand treatment patterns and outcomes in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of multiple sclerosis (MS)
- You are 18 years old or older
- You are willing to share personal information for the registry
- You are starting or recently got prescribed an MS medicine at the time you enroll
- You are not (and do not plan to) join a double-blind, randomized MS drug study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds a patient-powered research network for people living with multiple sclerosis. It may help by gathering real-world information from patients to improve understanding of the disease over time.
This study is a registry (a voluntary database) for people diagnosed with multiple sclerosis or a related first episode called clinically isolated syndrome. It helps researchers learn about how these conditions affect people over time.
This study creates a registry for people with multiple sclerosis (MS) to track their health over time. The information gathered may help researchers better understand MS and improve care.
This trial is looking at how people with multiple sclerosis experience clinical study enrollment and participation. It may help improve how future MS trials work and are explained, especially for different types of participants.
This is a registry study that collects health information from people with multiple sclerosis and related conditions. By joining, you help researchers better understand these diseases and improve future treatments.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.